In the first quarter of fiscal 2025, HOLX is expected to have benefited from expanding breast health offerings.
Hologic (HOLX) concluded the recent trading session at $71.77, signifying a -1.35% move from its prior day's close.
In the first quarter of fiscal 2025, HOLX is expected to have benefited from the strength of its core franchises.
In the closing of the recent trading day, Hologic (HOLX) stood at $71.19, denoting a +1.17% change from the preceding trading day.
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions. Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below.
HOLX touched a new yearly low this week, reflecting market reaction to its mixed Q1 fiscal 2025 results. Still, the stock offers strong rebound potential.
In the closing of the recent trading day, Hologic (HOLX) stood at $70.20, denoting a -0.13% change from the preceding trading day.
In the closing of the recent trading day, Hologic (HOLX) stood at $72.73, denoting a +0.05% change from the preceding trading day.
Hologic completes the acquisition of Gynesonics, developer of the Sonata System, for approximately $350 million.
Hologic (HOLX) concluded the recent trading session at $71.74, signifying a -0.49% move from its prior day's close.
Hologic's strength in the Surgical wing instills optimism among investors. Yet, currency impacts raise concerns.